Home Free Dental Care States Medicaid Submit Procedure List Foreign Research Contact

Dental Research Programs in Bethesda MD

Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth

This study is currently recruiting patients

Verified by National Institutes of Health Clinical Center (CC) November 2006

Sponsored by: National Institute of Dental and Craniofacial Research (NIDCR)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00104026


This study will examine common features of gingival overgrowth (excessive growth of the gums around the teeth) that develops in patients with the hereditary form of the condition and in those who develop the condition as a side effect of medications. A better understanding of gingival overgrowth may help scientists develop medications with fewer oral side effects.

Patients of any age with hereditary gingival fibromatosis and their blood relatives, and patients of any age with gingival overgrowth who are taking medications associated with development of the disorder, including phenytoin (diphenylhydantoin or Dilantin), cyclosporine, and calcium-channel blockers, may be eligible for this study.

Participants undergo a medical and dental history, including a history of medication use; detailed examination of the teeth, periodontium, head, and neck; photographs of teeth with gingival overgrowth; dental x-rays; and blood tests. DNA is extracted from a blood sample to look for genes related to gingival overgrowth.

Patients with gingival overgrowth are offered two options, as follows:

Tissue biopsy: A tissue sample is taken from each affected site, with a maximum of three biopsies. For the procedure, lidocaine is first injected into the gum to numb the tissue. Then, a cookie-cutter instrument is pushed into the numbed skin, and a small piece of tissue is removed. Gingivectomy: Surgical removal of the overgrown gingival.

Gingival Overgrowth

Study Type: Observational
Study Design: Natural History

Official Title: Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth

Further study details as provided by National Institutes of Health Clinical Center (CC):

Expected Total Enrollment:  600

Study start: February 2005

The purpose of this protocol is twofold: 1) to continue identification of genes associated with hereditary gingival fibromatosis (HGF), a type of gingival overgrowth 2) to investigate the genes up-regulated by medications that induce gingival overgrowth. These studies will establish if common mechanisms are involved in the hereditary and drug-induced processes. If a common pathway is identified, it could lead to the development of assays that could be used to screen new medications for their potential deleterious effects on periodontal tissues. In addition, understanding the mechanisms involved in gingival overgrowth could lead to the development of tissue engineering approaches to repair gingival defects. Genes will be identified from DNA samples collected from patients with hereditary gingival fibromatosis. These will be compared with DNA and tissue samples taken from patients taking medications known to induce gingival overgrowth (phenytoin, cyclosporine and calcium channel blockers).


Genders Eligible for Study:  Both

Accepts Healthy Volunteers


Patients of any age, gender, and racial/ethnic group with hereditary gingival fibromatosis (HFG) as diagnosed with HGF by clinical appearance that consists of attached gingival covering the lower 1/3 or more of the clinical crowns of teeth in an individual not taking medications associated with gingival changes.

Blood relatives of affected individuals who are at risk of inheriting HGF.

Patients of any age, gender, and racial/ethnic group taking one of the three medications associated with drug-induced gingival overgrowth (phenytoin diphenylhydantoin or Dilantin, cyclosporine, or calcium-channel blockers).

Patients with six or more teeth.


Patients with significant cognitive impairment.

Pregnant patients or lactating patients.

Patients unwilling to give informed consent.

Patients with less than six teeth.

Patients unable to sign informed consent will be excluded from the study.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00104026

Patient Recruitment and Public Liaison Office      (800) 411-1222    prpl@mail.cc.nih.gov
TTY      1-866-411-1010 

      National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda,  Maryland,  20892,  United States; Recruiting

North Carolina
      Wake Forest University, Winston-Salem,  North Carolina,  27103,  United States; Recruiting

      University of Pittsburgh, Pittsburgh,  Pennsylvania,  15261,  United States; Recruiting

      Universidade de Taubate, Taubate,  Brazil; Recruiting

More Information

NIH Clinical Center Detailed Web Page


Ellis JS, Seymour RA, Taylor JJ, Thomason JM. Prevalence of gingival overgrowth in transplant patients immunosuppressed with tacrolimus. J Clin Periodontol. 2004 Feb;31(2):126-31.

Study ID Numbers:  050103; 05-D-0103
Last Updated:  December 12, 2006
Record first received:  June 19, 2006
ClinicalTrials.gov Identifier:  NCT00104026
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2006-12-26

[Home]   [State Directory]   [Free Treatment]   [Foreign Directory]   [Contact]   [Submit Research]  
Dentistry Research Programs Directory
Bethesda Maryland MD
A Featured part of
Dental Research Programs featured in Dental Health Library
Oral Health Research Issues in Dentistry
All rights reserved - 1999-2014
Powered by DentMedHost